



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_231_25

You asked:

I am conducting analysis on drugs used to treat inflammatory diseases and kindly request your help.

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) for the three-month period specified within the question.

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Appendix A

Q1a – How many patients were treated with the following drugs from the following departments (for any disease) from the start of Jan 2025 to the end of Mar 2025?

Please use the latest available 3 months if Jan to Mar is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept			
Guselkumab			
Infliximab (Remicade)			
Infliximab (Biosimilars)			
Ixekizumab			
Risankizumab			
Secukinumab			
Tildrakizumab			
Ustekinumab			
Upadacitinib			
Vedolizumab			
Filgotinib			
Golimumab			
Mirikizumab			
Ozanimod			
Etrasimod			
Tofacitinib			

Baricitinib			
Rituximab			
Sarilumab			
Tocilizumab			

Q1b – How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of Jan 2025 to the end of Mar 2025?

Please use the latest available 3 months if Jan to Mar is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)			
Ustekinumab (Pyzchiva)			
Ustekinumab (Uzpruvo)			
Ustekinumab (Wezenla)			

Our response:

Please find below the tables you have provided populated with the information Medicines Management are able to provide at this current time. The period the data relates to 1st January 2025 to the 31st March 2025 as requested.

Q1a.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab	70	250	507
Apremilast	11		**
Bimekizumab	17		27
Brodalumab	**		
Certolizumab Pegol	**	**	74
Deucravacitinib	16		
Etanercept			290
Guselkumab	46		**
Infliximab (Remicade)		**	
Infliximab (Biosimilars)	**	250	23
Ixekizumab	23		24
Risankizumab	61	8	
Secukinumab	61		99
Tildrakizumab	11		
Ustekinumab	10	183	21
Upadacitinib	12	35	31
Vedolizumab		217	
Filgotinib		**	8
Golimumab			56
Mirikizumab			
Ozanimod		**	
Etrasimod			
Tofacitinib			10

Baricitinib	5		39
Rituximab			46
Sarilumab			5
Tocilizumab			91

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q1b.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)	5	36	7
Ustekinumab Biosimilars	5	147	14

Unfortunately, we are unable to provide the biosimilars individually as requested due to the low numbers involved (S40 applied – please see response to Q1a). However, to enable us to provide you with some data, they have grouped them together.